Moderna, Inc.
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214
Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4-5)) are approved for use in individuals 12 years of age and older in the European Union
Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4-5) in Phase 2/3 clinical trials
CAMBRIDGE, MA / ACCESSWIRE / December 16, 2022 / Moderna, Inc.(Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the marketing authorization (MA) to include a booster dose of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), at the dose level for children (6-11 years) of 12.5mcg/12.5mcg (0.25 mL) at least three months after the last prior dose of a COVID-19 vaccine.
"The recommendation to authorize the use of a booster dose of mRNA-1273.214 in children ages 6-11 is crucial to providing protection against Omicron and the emergence of new variants of concern, which is especially important during the winter period in Europe when respiratory diseases are on the rise," said Stéphane Bancel, Chief Executive Officer of Moderna. "We are grateful to the CHMP for their review of our submission and look forward to an authorization decision from the European Commission."
The pediatric application is based on clinical trial booster data for Moderna's original vaccine, Spikevax, which was administered to over a thousand participants. The application described data from a 25 μg booster dose administered to children ages 6 to 11 years old following a completed primary series of the Moderna COVID-19 vaccine. In addition, the application included clinical trial data from a Phase 2/3 studying mRNA-1273.214.
In November 2022, Moderna announced that its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4-BA.5) in Phase 2/3 clinical trials. Both bivalent vaccines also met non-inferiority immunogenicity criteria to the original strain.
A Phase 2/3 trial evaluating mRNA-1273.214 as booster and primary series in children 6 months through 5 years of age is currently underway, with initial results expected in early 2023.
About Moderna
In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's development of bivalent vaccine candidates against COVID-19 (mRNA-1273.222 and mRNA-1273.214); the ability of mRNA-1273.214 to protect children against COVID-19; the ability of mRNA-1273.214 and mRNA-1273.222 to induce higher neutralizing antibody titers against Omicron variants in adults than the Company's vaccine candidate against the ancestral strain of SARS-CoV-2 (mRNA-1273); and the pending authorization of mRNA-1273.214 in the European Union for administration in children ages 6-11 following the CHMP's positive opinion. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts:
Media:
Luke Mircea Willats
Director, Corporate Communications
Luke.Mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
https://www.accesswire.com/732159/EMA-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Recommends-the-Use-of-Modernas-BA1-Targeting-Bivalent-COVID-19-Booster-in-Children-6-11-Years-In-the-European-Union
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision Announces First Quarter 2025 Results12.5.2025 16:05:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / May 12, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its first quarter 2025 results. Key Business Highlights Established defense industry advisory board to accelerate strategic expansion and pursuit of revenue opportunities in the defense tech and military sectors. Elevated momentum toward near-term revenue opportunities from multiple leading industrial companies in the autonomous mobile robot (AMR) and automated guided vehicle (AGV) sector. Deepened executive leadership expertise, onboarding Glen DeVos, former CTO of Aptiv, as MicroVision's Chief Technology Officer, leading the Company's innovative product roadmapping and enhanced go-to-market strategy. Continued engagement with top-tier global automotive OEMs, with seven high-volume RFQs for passenger vehicles and custom development opportunities. Ramped production to meet anticipated volume demand, ensur
Nestlé and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona9.5.2025 04:20:00 CEST | Press release
BARCELONA, ES / ACCESS Newswire / May 9, 2025 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Symposium/Xpo™ 2025 to attend Nestlé's solution provider session on May 19. The presentation will highlight how the company is transforming its supply chain across brands and regions using OMP's Unison PlanningTM. In this session, Shannon Novack, Supply Chain Excellence Expert at Nestlé, will share how the global food and beverage leader is reimagining its supply chain planning to meet increasing customer expectations in a fast-changing business environment. By leveraging advanced planning technology like Unison Planning, managing organizational change, and scalingfuture-fit capabilities, Nestlé is delivering real results. Attendees will gain valuable insights into how the company is driving adoption, overcoming transformation challenges, and aligning technology speed with organizational agility. The Gartner Supply Chain Symposium/Xpo
Innodata Reports First Quarter 2025 Results with Revenue up 120% Year-Over-Year and Reaffirms Growth Guidance of 40% or more for 20258.5.2025 16:45:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2025. Revenue of $58.3 million, representing 120% revenue growth year-over-year. Adjusted EBITDA of $12.7 million, an increase of $8.9 million from $3.8 million in the same period last year.* Net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, compared to a net income of $1.0 million, or $0.03 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $56.6 million as of March 31, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "We had a strong start to the year. We're being onboarded by potential major new customers, expanding existing relationships, and building a pipeline that's deeper and more advanced than at any point in our history. We are bringing ideas and innovation to our customers that are being w
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft8.5.2025 12:00:00 CEST | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 8, 2025 / The UK's Military Aviation Authority has issued a Military Type Certificate to the Royal Air Force's Protector RG Mk1 uncrewed aircraft, also designated the MQ-9B, certifying that it has passed a rigorous airworthiness assessment and verifying it's safe to operate without geographic restrictions, including over populous areas. This April 29 decision was a first-of-its-kind milestone for a large, unmanned aircraft system. It's a huge accomplishment for the UK and a technological watershed in the history of unmanned aircraft systems. GA-ASI is the first manufacturer of large, unmanned aircraft to receive an MTC based on rigorous compliance with STANAG 4671, the NATO standard for unmanned aircraft system airworthiness. Obtaining the MTC has been a goal of GA-ASI since the inception of the MQ-9B in January 2014. The company took its proven UAS platform, the MQ-9A, and added performance enhancing features while ensuring that the design
The Battery Show Europe 2025 Critical Agenda Highlights Moves to Global Collaboration, Regulation and Supply Chain Resilience8.5.2025 04:00:00 CEST | Press release
Featuring speakers from BMW, CATL, Mercedes Benz, Cellforce and more. STUTTGART, GERMANY / ACCESS Newswire / May 8, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany, the region's only dedicated event for battery manufacturing, electric and hybrid vehicle tech industries, has announced its 2025 keynote lineup. The sessions will cover key themes including upcoming supply chain, navigating regulatory and policy changes and staying ahead of the curve on market trends with analysis. "Better Together: Building Resilient Battery Supply Chains Through International Collaboration," opens the program moderated by James Frith, Principal at Volta Energy Technologies, featuring insights from Isobel Sheldon, Global CEO at Western CAM Inc, Ulderico Ulissi, Head of Overseas Tech & Start-up Cooperation at CATL, Jerry Fang, Director of Business Development at Shanghai Putailai New Energy Technology Co., Ltd. and Benoit Lem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom